Fluciclatide

DB14842InvestigationalSmall molecule

Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis. The conditions targeted by... The conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms.

Mechanism: Pharmacologically active on Integrin beta-3, Integrin alpha-V, and Integrin beta-5
Curator reviewed
Formula / weight: C₇₅H₁₁₅FN₁₈O₂₇S₃ · 1816.02 g/mol (avg)
Code names: AH-111585

Resolves to

Compound

UNIIUQ6CV583Q3CAS879894-00-5

Structure

InChIKeyVXFFXZSNVKXXIB-XVUFQIMXSA-NSMILES

NC(=O)COCC(=O)NCCOCCOCCOCCNC(=O)[C@@H]1CSCC(=O)N[C@@H](CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO\N=C\C2=CC=C(F)C=C2)C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N1

Targets

P05106ITGB3P06756ITGAVP18084ITGB5

What you can answer from here — as of August 31, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fluciclatide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account